05062nam 2200733 450 991013147170332120200520144314.01-118-93697-31-118-93699-X1-118-93698-1(CKB)3710000000476437(EBL)4093343(SSID)ssj0001553127(PQKBManifestationID)16170925(PQKBTitleCode)TC0001553127(PQKBWorkID)14812729(PQKB)10558905(PQKBManifestationID)16176183(PQKB)22566357(MiAaPQ)EBC4093343(DLC) 2015034222(Au-PeEL)EBL4093343(CaPaEBR)ebr11119457(OCoLC)936865300(PPN)204669774(EXLCZ)99371000000047643720151209h20162016 uy 0engur|n|---|||||txtccrThe treatment of epilepsy /edited by Simon Shorvon, Emilio Perucca, Jerome Engel, Jr. ; contributors, Patrick Adjei [and one hundred thirty others]Fourth edition.Chichester, England :Wiley Blackwell,2016.©20161 online resource (2765 p.)Description based upon print version of record.1-118-93700-7 Includes bibliographical references and index.Title page; Copyright; List of Contributors; Preface to the Fourth Edition; Preface to the First Edition; Historical Introduction The Drug Treatment of Epilepsy from 1857 to 2015; Commentary; Acknowledgement; References; Section I Introduction; 1 Definition (Terminology) and Classification in Epilepsy: A Historical Survey and Current Formulation, with Special Reference to the ILAE; Definition; Classification; The future of classification schemes of epilepsy; Definition; Definition and classification - status epilepticus; Afterthought; Acknowledgement; References2 Differential Diagnosis of EpilepsyIntroduction; General approach to the diagnosis of episodic disturbances; Syncope; Non-epileptic seizures; Panic disorder; Migraine; Sleep disorders; Vertigo; Movement disorders; Cerebral ischaemia; Endocrine and metabolic abnormalities; Transient global amnesia; References; 3 Mechanisms of Epileptogenesis; Membrane ion channels; Membrane ion channels as targets for antibodies in acquired autoimmune disorders; Network and system involvement in epileptogenesis; Epileptogenesis as a process; New targets for antiepileptic and antiepileptogenic strategiesConclusionsReferences; 4 Antiepileptic Drug Discovery; Characteristics of the ideal model system; The current era of AED discovery; Anticonvulsant Screening Program; Early identification of antiepileptic activity; MES, scPTZ and 6-Hz tests; Differentiation of anticonvulsant activity; Pharmacological profile and potential clinical utility; Pharmacoresistant seizure models; Therapeutic index and toxicity assessment; Aetiologically relevant model systems; Beyond the seizure; Antiepileptogenesis and disease modification (see also Chapter 8); Conclusions; Acknowledgement; References5 Antiepileptic Drug DevelopmentIntroduction; Overview on clinical studies and trials for drug development; Opportunities for developing better antiseizure AEDs; Development of epilepsy drugs beyond suppressing seizures; Conclusions; Acknowledgements; References; 6 Mechanisms of Antiepileptic Drug Action; Main targets; Other targets; References; 7 Mechanisms of Drug Resistance and Tolerance; Introduction; The concept of drug resistance in epilepsy; Disease-related mechanisms of drug resistance in epilepsy; Drug-related mechanisms of drug resistance in epilepsyPharmacogenetic mechanisms of drug resistance in epilepsyProof-of-concept of drug resistance hypotheses; Conclusions; References; 8 Epilepsy Biomarkers; Introduction; Need for biomarkers; Mechanisms of epilepsy; Potential biomarkers; Research to identify biomarkers; Acknowledgements; References; Section II Principles of Medical Management; 9 General Principles of Medical Management; Aims of treatment; When should treatment be started?; Initiation of treatment and dose optimization; Assessing clinical response; What next when the initial treatment fails? - monotherapy and combination therapyHow long should treatment be continued?EpilepsySurgeryAnticonvulsantsTherapeutic useEpilepsyChemotherapyEpilepsySurgery.AnticonvulsantsTherapeutic use.EpilepsyChemotherapy.617.481Shorvon S. D(Simon D.),Perucca EmilioEngel JeromeJr.,Adjei PatrickMiAaPQMiAaPQMiAaPQBOOK9910131471703321Treatment of epilepsy805515UNINA